A review on pityriasis rubra pilaris

D Wang, VCL Chong, WS Chong, HH Oon - American journal of clinical …, 2018 - Springer
Pityriasis rubra pilaris (PRP) is an idiopathic, papulosquamous inflammatory dermatosis. It is
characterized by hyperkeratotic follicular papules coalescing into orange-red scaly plaques …

Pityriasis rubra pilaris: algorithms for diagnosis and treatment

S Roenneberg, T Biedermann - Journal of the European …, 2018 - Wiley Online Library
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women
of all ages and also children. The clinical appearance of PRP is highly variable, as is the …

CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris

BG Craiglow, LM Boyden, R Hu, M Virtanen… - Journal of the American …, 2018 - Elsevier
Background Heterozygous mutations in caspase recruitment domain family member 14
gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis …

Systemische Therapien bei Pityriasis rubra pilaris: eine systematische Übersicht

C Kromer, R Sabat, D Celis… - JDDG: Journal der …, 2019 - Wiley Online Library
Pityriasis rubra pilaris (PRP) ist eine seltene papulosquamöse Erkrankung. Die Behandlung
ist schwierig; das therapeutische Arsenal umfasst topische Corticosteroide, Phototherapie …

Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients

NA Ross, HJ Chung, Q Li, JP Andrews… - JAMA …, 2016 - jamanetwork.com
Importance Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder with limited
epidemiologic and clinicopathologic data. Little information is available on long-term …

Biologics for pityriasis rubra pilaris treatment: a review of the literature

M Napolitano, D Abeni, B Didona - Journal of the American Academy of …, 2018 - Elsevier
Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease that is
often refractory to conventional therapies. The off-label use of biologics, such as anti–tumor …

Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial

D Haynes, JL Strunck, CA Topham… - JAMA …, 2020 - jamanetwork.com
Importance Pityriasis rubra pilaris is a rare and disabling cutaneous disease that is
frequently recalcitrant to conventional therapies and appears to involve interleukin (IL)-17 …

Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14

O Eytan, O Sarig, E Sprecher… - British Journal of …, 2014 - academic.oup.com
M. chelonae, M. fortuitum or M. peregrinum arising in patients with diabetes using insulin
pen devices or syringe and needles have been reported. 8, 9 Identification of …

Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14

SM Lwin, CK Hsu, L Liu, HY Huang… - British Journal of …, 2018 - academic.oup.com
Pityriasis rubra pilaris (PRP) represents a group of rare chronic inflammatory skin disorders
in which around one in 20 affected individuals show autosomal dominant inheritance. In …

New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab

M Kurzeja, L Rudnicka, M Olszewska - American journal of clinical …, 2011 - Springer
Abstract Interleukin (IL)-23 is an important regulator of T helper-17 lymphocytes, which
influence the cutaneous immune system by production of IL-17 and several other …